U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H23NO5.ClH
Molecular Weight 381.851
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRETOQUINOL HYDROCHLORIDE ANHYDROUS

SMILES

Cl.COC1=CC(C[C@@H]2NCCC3=CC(O)=C(O)C=C23)=CC(OC)=C1OC

InChI

InChIKey=UHSXRTHJCJGEKG-UQKRIMTDSA-N
InChI=1S/C19H23NO5.ClH/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14;/h7-10,14,20-22H,4-6H2,1-3H3;1H/t14-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf

Trimetoquinol hydrochloride dilates bronchial muscle selectively by stimulating Beta 2-receptors. It is used for the relief of bronchoconstriction associated with bronchitis, asthmatic bronchitis and bronchial asthma. Since the concurrent use of the drug with catecholamines such as Epinephrine and Isoproterenol may induce arrythmia or cardiac arrest in some cases, concurrent use is not recommended. Adverse reactions : Palpitation may occur occasionally, and alteration of blood pressure and precordial pain may appear rarely; headache may occur occasionally; tremor, dizziness, feverish sensation may also be encountered in a rare incidence; occasionally, nausea and anorexia may appear.

Originator

Yamato, E.|Hirakura, M.|Sugasawa S.
3
Curator's Comment: Mitsubishi Tanabe Pharma Corporation transferred the marketing rights of Inolin (Ingredient – Trimetoquinol) to its subsidiary, Tanabe Seiyaku Hanbai Co.Ltd at April 1, 2011. http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/e_110307.pdf

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 7.34 null [pKi]
Agonist
2752
 6.49 null [pKi]
Agonist
2752
 5.43 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Inolin

Approved Use

It is given as the bronchodilating agent in the management of reversible airways obstruction, as in asthma.
Chronic obstructive pulmonary disease
175
Sources: www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf
 Palliative
Approved
8583
Inolin

Approved Use

It is given as the bronchodilating agent in the management of reversible airways obstruction, as in chronic obstructive pulmonary disease.
Palliative
Approved
8583
Inolin

Approved Use

It is used to treat chronic bronchitis.
PubMed

PubMed

TitleDatePubMed
Errors in opioid prescribing: a prospective survey in cancer pain.
2010-04
Eyelid localization in mantle cell lymphoma: long-lasting complete remission after surface brachytherapy.
2009-08-20
Plasma and urinary concentrations of trimetoquinol by LC-MS-MS following intravenous and intra-tracheal administration to horses with heaves.
2008-12
The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study.
2008-08
[Yersinia psuedotuberculosis septicemia in a healthy young woman].
2008-03
Identification and characterization of a novel peptide ligand of Tie2 for targeting gene therapy.
2008-03
Trimetoquinol: bronchodilator effects in horses with heaves following aerosolised and oral administration.
2007-05
Intravenous and intratracheal administration of trimetoquinol, a fast-acting short-lived bronchodilator in horses with 'heaves'.
2006-11
Endoscopic video-assisted breast surgery: procedures and short-term results.
2006-08
1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diols as novel affinity and photoaffinity probes for beta-adrenoceptor subtypes.
2006-03-15
Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial.
2006-02
Single-incision, minimally invasive total hip arthroplasty: length doesn't matter.
2004-12
Beta-adrenoreceptor agonists for diffuse esophageal spasm.
2002
Biochemical activities of trimetoquinol analogs at human beta(1)- and beta(3)-adrenergic receptors.
2001-01
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous and intratracheal administration of trimetoquinol are tested also: http://www.ncbi.nlm.nih.gov/pubmed/17124848 http://www.ncbi.nlm.nih.gov/pubmed/17124848 http://www.ncbi.nlm.nih.gov/pubmed/963963 http://www.ncbi.nlm.nih.gov/pubmed/971582
3-12 mg per day (in 2-3 separate doses)
Route of Administration: Oral
In Vitro Use Guide
Pre-incubation of platelet microsomes with Trimethoquinol (10-100 ug/ml) for up to 4 min didn’t suppress production of Thromboxane A2-like activity.
Name Type Language
ANHYDROUS TRETOQUINOL HYDROCHLORIDE
MART.  
Preferred Name English
TRETOQUINOL HYDROCHLORIDE ANHYDROUS
Common Name English
TRIMETHOQUINOL HYDROCHLORIDE
Common Name English
TRETOQUINOL L-FORM HYDROCHLORIDE [MI]
Common Name English
ANHYDROUS TRETOQUINOL HYDROCHLORIDE [MART.]
Common Name English
(-)-1,2,3,4-TETRAHYDRO-1-(3,4,5-TRIMETHOXYBENZYL)ISOQUINOLINE-6,7-DIOL HYDROCHLORIDE
Systematic Name English
6,7-ISOQUINOLINEDIOL, 1,2,3,4-TETRAHYDRO-1-((3,4,5-TRIMETHOXYPHENYL)METHYL)-, HYDROCHLORIDE (1:1), (1S)-
Common Name English
TRETOQUINOL L-FORM HYDROCHLORIDE
MI  
Common Name English
Code System Code Type Description
MERCK INDEX
m11019
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID1048756
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY
SMS_ID
100000077521
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY
FDA UNII
298SP836N4
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY
PUBCHEM
656634
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY
ECHA (EC/EINECS)
242-423-5
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY
CAS
18559-59-6
Created by admin on Mon Mar 31 21:32:56 GMT 2025 , Edited by admin on Mon Mar 31 21:32:56 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of TRETOQUINOL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966